A new generation of supplements have become a billion-dollar business, containing antioxidants that slow the development of macular degeneration, a leading cause of blindness. But according to a researcher, many on the market may not contain the level of antioxidants that they claim on the label.
VANCOUVER, British Columbia, June 03, 2021 (GLOBE NEWSWIRE)
Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that its US-based OTC Markets listing under the symbol “OPTHF” has received approval from the Depository Trust Company (“DTC”) to make the Company’s common shares eligible to be electronically cleared and settled through DTC (“DTC Eligibility”).
DTC is a subsidiary of the Depository Trust and Clearing Corporation, a United States company that manages the electronic clearing and settlement of publicly traded companies. DTC Eligibility incorporates an electronic method of clearing securities that speeds up the receipt of stock and cash, and thus accelerates the settlement process for certain investors. DTC is a member of the U.S. Federal Reserve System, a limited-purpose trust company unde
Canada, long regarded a pioneer in drug policy reform, is now trying to move the needle on patient access to psilocybin, the active ingredient in “magic mushrooms.”
The country’s history with early cannabis legalization has placed it at the center of attention in the psychedelics scene, as patients, advocates and healthcare professionals seek to expand access to psychedelics-assisted therapy.
Since 2020, Health Canada has allowed over 50 patients and doctors to legally use psilocybin through special government-granted exemptions. However, pressure is building for alternative solutions that can guarantee access to more people in a more agile way.
How Are Patients In Canada Accessing Psilocybin Treatment Today?
By Chris Johnston, Senior Account Executive – Carton & Labels, Jones Healthcare Group
Any change to packaging design for an approved pharmaceutical product is a time consuming, detail-orientated effort, even with small brand-driven changes––so when governments update packaging regulations on a larger scale, a company’s entire product line could be impacted, creating change management projects for sometimes hundreds of items. What’s more, if updated regulations introduce new requirements for packaging, this not only adds another layer of complexity, but also presents a significant challenge to any organization given the significant internal resource time and workload necessary to manage changes at this scale.